# An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis

> **NCT01743560** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Oestrogen Receptor Positive Advanced Breast Cancer

## Interventions

- **DRUG:** RAD001
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT01743560
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-31
- **Primary completion:** 2016-08-15
- **Final completion:** 2016-08-15
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2019-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01743560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01743560, "An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01743560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*